Log in to add personal notes on this page.
A 14-year-old reports gradually worsening central vision over 2 years; reading and recognizing faces have become difficult. Acuity is 20/80 OU with normal peripheral visual fields. Fundoscopy shows yellow-white pisciform (fish-shaped) flecks at the posterior pole and a "beaten-bronze" macula. Fluorescein angiography shows the characteristic dark choroid sign. Molecular testing identifies biallelic ABCA4 pathogenic variants.
| Form | Inheritance | Gene | Notes |
|---|---|---|---|
| Stargardt 1 (STGD1), ~95% of cases | AR | ABCA4 | Photoreceptor-specific ATP-binding cassette transporter that clears all-trans-retinal from outer segments; loss → toxic bisretinoid (lipofuscin/A2E) accumulates in RPE |
| Stargardt 3 (STGD3) | AD | ELOVL4 | Long-chain fatty acid elongase; rare |
| Stargardt 4 (STGD4) | AD | PROM1 | Photoreceptor disc morphogenesis; can also cause cone-rod dystrophy and retinitis pigmentosa |
ABCA4 is one of the most allelically diverse disease genes:
- Hundreds of pathogenic variants described
- Deep-intronic and splice-region variants are common: when standard exon sequencing finds only one variant, extended testing (deep-intronic, MLPA for del/dup, sometimes RNA studies) is required
- Carrier frequency in general population is meaningfully high (~1/30-50); pseudodominance in pedigrees is possible
In healthy photoreceptors, ABCA4 (an importer / inward flippase) transports N-retinylidene-PE from the luminal leaflet of the disc to the cytoplasmic leaflet after photoisomerization, allowing all-trans-retinal to enter the visual cycle. Without ABCA4:
- N-retinylidene-PE accumulates in the disc lumen
- Reacts with another all-trans-retinal → forms A2E (a bisretinoid lipofuscin component)
- Accumulates in RPE lipofuscin → RPE toxicity → photoreceptor death
- Fundus autofluorescence (FAF) is markedly elevated in early disease, then darkens as RPE atrophies
This mechanism is the basis for the vitamin A counseling pearl; see Counseling below.
- Onset: typically childhood to adolescence (juvenile macular dystrophy); later-onset adult forms also occur (often milder, later genotype)
- Symptoms: bilateral central vision loss, difficulty with reading and faces; often progresses to legal blindness (~20/200 to count fingers); peripheral vision usually preserved (cone-rod pattern)
- Fundus findings:
- Yellow-white pisciform (fish-shaped) flecks at the macula and posterior pole
- "Beaten-bronze" or "snail-slime" appearance of the macula
- Eventual macular atrophy ("bull's-eye" maculopathy in some)
- Fluorescein angiography: dark choroid sign; the densely packed RPE lipofuscin masks normal background choroidal fluorescence (highly characteristic; not seen in most other macular dystrophies)
- Fundus autofluorescence (FAF): markedly elevated AF early; areas of decreased AF as atrophy develops
- Electroretinogram (ERG): normal initially; cone (then rod) responses decline with disease progression
- OCT: disruption of the ellipsoid zone and outer nuclear layer in the central macula
- Clinical exam + multimodal imaging (fundus, FAF, OCT, FA) is highly suggestive
- ABCA4 molecular testing: comprehensive panel including deep-intronic variants and del/dup analysis when first-pass sequencing finds only one variant
- If ABCA4 negative, broaden to inherited retinal dystrophy panel (covers ELOVL4, PROM1, PRPH2, and the broader IRD differential)
- Avoid high-dose vitamin A supplementation in ABCA4-related Stargardt: vitamin A enters the visual cycle and accelerates lipofuscin/A2E accumulation. This contrasts with RPE65-related retinal dystrophy where vitamin A intake is therapeutically relevant. Distinguish by genotype before counseling.
- UV light protection (sunglasses) recommended
- High carrier frequency in general population → pseudodominant inheritance possible; clarify by molecular testing of partner before counseling about offspring risk
- AR: sibling recurrence 25%
- Low-vision services, magnifiers, screen-reading software
- Vocational support, education accommodations
- Vitamin A avoidance + UV protection
- Investigational therapies:
- Visual cycle modulators (e.g., emixustat, ALK-001 / gildeuretinol) aim to reduce A2E formation
- Subretinal AAV gene therapy for ABCA4 is technically challenging because of the gene's large size (cDNA ~6.8 kb exceeds AAV cargo); dual-AAV and lentiviral approaches are in trials
- Stem cell-derived RPE transplantation in early-stage trials
- Cone-rod dystrophy: broader cone+rod loss earlier; ERG abnormal sooner
- Best disease (vitelliform macular dystrophy): BEST1; egg-yolk lesion, abnormal EOG
- Pattern dystrophy: PRPH2; older onset, usually milder
- Macular dystrophy after chronic chloroquine/hydroxychloroquine: bull's-eye maculopathy, drug history
- Retinitis pigmentosa with macular involvement: bone-spicule pigmentation, abnormal rod ERG predominantly